What Key Growth Drivers Are Shaping The Adalimumab, Infliximab and Etanercept Biosimilars Market Forecast Toward $7.34 Billion?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Big Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Today And What Is Its Future Size?
The market space for biosimilars including adalimumab, infliximab, and etanercept has expanded swiftly in the past few years. It is projected to surge from $4.37 billion in 2024 to $4.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.6%. The notable growth experienced in the historical period is the outcome of boosted healthcare spending, alterations in regulations, governmental initiatives, and escalating healthcare expenses.
The biosimilars market for adalimumab, infliximab, and etanercept is projected to exhibit speedy expansion in the near future, reaching a total market value of $7.34 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. This expected surge during the forecast period can be attributed to factors such as increased spending on healthcare, an ageing demographic, and improved access to healthcare facilities driving the market’s growth. The predominant trends anticipated within this forecast span include the emphasis on the launch of new products, concentration on mergers and acquisitions, prioritising strategic collaborations, and augmenting investments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
What Growth-Enabling Forces Are Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab, and etanercept biosimilars market is influenced by the expiry of patents for branded drugs, which opens the door for biosimilars. For example, in the United States, Hospira (a Pfizer Inc. subsidiary) obtained FDA approval for Inflectra, intended for the treatment of various autoimmune diseases including rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, after the branded drug Remicade’s patent expired. In a similar scenario, the patent for Amgen’s Enbrel expired in the EU, leading to the European Commission’s approval of Benepali, a biosimilar of Enbrel. The ending of Humira’s patent resulted in the availability of its biosimilars on the market. Hulio, the sixth biosimilar of Humira, received recent FDA approval. Thus, the end of patents for branded biologic drugs like Humira, Enbrel, and Remicade enhances the demand for adalimumab, infliximab, and etanercept biosimilars in the market.
Which Segments Define The Structure Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
What Strategic Shifts And Innovations Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market?
Leading businesses in the adalimumab, infliximab, and etanercept biosimilars market are honing their focus on creating unique solutions, such as the citrate-free adalimumab, to enhance customer experiences. Citrate-free adalimumab is a version of the biological drug adalimumab, formulated without the inclusion of citrate. To illustrate, Fresenius Kabi, a Germany-domiciled pharmaceutical and medical technology company, revealed the FDA authorization for its biosimilar Idacio (adalimumab) in December 2022. It is intended for managing chronic autoimmune disorders, conforming to all allowable usages of the reference drug. Taking advantage of advanced analytical techniques, it’s been created to treat a variety of chronic diseases.
Which Firms Are Making The Biggest Impact In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market In The Coming Years?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
